GoodRx (GDRX)
Matches consumers with prescription prices, discounts, subscriptions and manufacturer affordability services.
$3.42
vs last close+0.03 (+0.88%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 180 | 197 | 198 | 201 | 195 | 199 | 203 | 203 | 196 | 195 | 194 | 200 |
| Cost of revenue | 19 | 15 | 12 | 12 | 12 | 12 | 13 | 33 | 13 | 17 | 42 | 21 |
| Gross profit | 161 | 181 | 185 | 189 | 184 | 186 | 190 | 170 | 183 | 177 | 152 | 179 |
| 200 | 200 | 178 | 169 | 163 | 168 | 166 | 142 | 168 | 155 | 133 | 156 | |
| Research & development | 40 | 32 | 31 | 31 | 30 | 32 | 31 | 30 | 31 | 29 | 30 | 27 |
| 127 | 124 | 131 | 121 | 115 | 117 | 114 | 113 | 116 | 103 | 108 | 107 | |
| Selling & marketing | 92 | 94 | 90 | 93 | 90 | 94 | 85 | 85 | 84 | 79 | 81 | 82 |
| General & administrative | 35 | 30 | 41 | 28 | 26 | 24 | 30 | 28 | 32 | 24 | 27 | 25 |
| Other expenses | 33 | 44 | 16 | 17 | 18 | 19 | 21 | −1 | 21 | 23 | −6 | 22 |
| Operating income | −38 | −18 | 7 | 20 | 20 | 18 | 23 | 28 | 15 | 23 | 20 | 24 |
| −8 | −6 | −7 | −8 | −12 | −7 | −7 | −8 | −9 | −8 | −14 | −8 | |
| Interest income | 9 | 8 | 8 | 6 | 5 | 5 | 4 | 3 | 2 | 2 | 1 | 1 |
| Interest expense | 15 | 15 | 15 | 15 | 12 | 11 | 11 | 11 | 11 | 10 | 10 | 10 |
| Other non-operating income | −6 | −8 | −8 | −6 | 0 | −5 | −4 | −3 | −2 | −2 | 4 | −2 |
| Income before tax | −47 | −25 | 0 | 12 | 8 | 11 | 17 | 20 | 6 | 14 | 6 | 15 |
| Income tax expense | −8 | 1 | 1 | 5 | 4 | 5 | 6 | 7 | 5 | 9 | 4 | 7 |
| Net income from continuing operations | −38 | −26 | −1 | 7 | 4 | 7 | 11 | 13 | 1 | 5 | 1 | 9 |
| Other adjustments | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −38 | −26 | −1 | 7 | 12 | 7 | 11 | 13 | 1 | 5 | 1 | 9 |
| EPS, basic | −$0.09 | −$0.06 | −$0.00 | $0.02 | $0.03 | $0.02 | $0.03 | $0.04 | $0.00 | $0.02 | $0.00 | $0.03 |
| EPS, diluted | −$0.09 | −$0.06 | −$0.00 | $0.02 | $0.03 | $0.02 | $0.03 | $0.04 | $0.00 | $0.02 | $0.00 | $0.02 |
| Weighted average shares, basic | 413 | 400 | 390 | 376 | 380 | 382 | 379 | 357 | 348 | 340 | 341 | 339 |
| Weighted average shares, diluted | 413 | 400 | 390 | 385 | 389 | 384 | 380 | 357 | 348 | 341 | 341 | 348 |
| EBITDA | 1 | 34 | 31 | 43 | 38 | 42 | 48 | 50 | 38 | 48 | 37 | 25 |
| Depreciation & amortization | 33 | 44 | 16 | 17 | 18 | 19 | 21 | 20 | 21 | 23 | 22 | 0 |
| EBIT | −32 | −10 | 15 | 26 | 20 | 23 | 27 | 30 | 17 | 25 | 15 | 25 |